Mankind Pharma [MANKIND] vs Torrent [TORNTPHARM] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Mankind Pharma Ltd. wins in 5 metrics, Torrent Pharmaceuticals Ltd. wins in 15 metrics, with 0 ties. Torrent Pharmaceuticals Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Mankind Pharma Ltd. | Torrent Pharmaceuticals Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 53.43 | 61.35 | Mankind Pharma Ltd. |
| Price-to-Book Ratio | 6.23 | 16.50 | Mankind Pharma Ltd. |
| Debt-to-Equity Ratio | 53.89 | 33.40 | Torrent Pharmaceuticals Ltd. |
| PEG Ratio | -1.36 | 2.35 | Torrent Pharmaceuticals Ltd. |
| EV/EBITDA | 30.12 | 34.44 | Mankind Pharma Ltd. |
| Profit Margin (TTM) | 12.79% | 17.83% | Torrent Pharmaceuticals Ltd. |
| Operating Margin (TTM) | 19.53% | 26.70% | Torrent Pharmaceuticals Ltd. |
| EBITDA Margin (TTM) | 19.53% | 26.70% | Torrent Pharmaceuticals Ltd. |
| Return on Equity | 13.67% | 25.18% | Torrent Pharmaceuticals Ltd. |
| Return on Assets (TTM) | 7.17% | 12.75% | Torrent Pharmaceuticals Ltd. |
| Free Cash Flow (TTM) | $18.83B | $19.73B | Torrent Pharmaceuticals Ltd. |
| Dividend Yield | 0.04% | 0.83% | Torrent Pharmaceuticals Ltd. |
| 1-Year Return | -0.01% | 40.54% | Torrent Pharmaceuticals Ltd. |
| Price-to-Sales Ratio (TTM) | 6.84 | 10.94 | Mankind Pharma Ltd. |
| Enterprise Value | $973.91B | $1,413.15B | Torrent Pharmaceuticals Ltd. |
| EV/Revenue Ratio | 7.00 | 11.09 | Mankind Pharma Ltd. |
| Gross Profit Margin (TTM) | 72.58% | 75.42% | Torrent Pharmaceuticals Ltd. |
| Revenue per Share (TTM) | $337 | $376 | Torrent Pharmaceuticals Ltd. |
| Earnings per Share (Diluted) | $43.14 | $67.11 | Torrent Pharmaceuticals Ltd. |
| Beta (Stock Volatility) | 0.39 | 0.19 | Torrent Pharmaceuticals Ltd. |
Mankind Pharma Ltd. vs Torrent Pharmaceuticals Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Mankind Pharma Ltd. | -0.03% | 0.97% | -4.90% | 13.63% | 11.17% | 9.96% |
| Torrent Pharmaceuticals Ltd. | -1.47% | 2.12% | 2.23% | 5.56% | 19.07% | 17.04% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Mankind Pharma Ltd. | -0.01% | 46.65% | 70.76% | 70.76% | 70.76% | 70.76% |
| Torrent Pharmaceuticals Ltd. | 40.54% | 146.00% | 215.51% | 578.42% | 2,737.14% | 10,046.95% |
Performance & Financial Health Analysis: Mankind Pharma Ltd. vs Torrent Pharmaceuticals Ltd.
| Metric | MANKIND | TORNTPHARM |
|---|---|---|
| Market Information | ||
| Market Cap | ₹946.57B | ₹1.39T |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 498,874 | 393,915 |
| 90 Day Avg. Volume | 593,334 | 399,129 |
| Last Close | ₹2,380.30 | ₹4,504.00 |
| 52 Week Range | ₹1,909.70 - ₹2,716.50 | ₹3,140.10 - ₹4,712.90 |
| % from 52W High | -12.38% | -4.43% |
| All-Time High | ₹3,054.80 (Dec 23, 2024) | ₹4,712.90 (May 25, 2026) |
| % from All-Time High | -22.08% | -4.43% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.10% | 0.18% |
| Quarterly Earnings Growth | 0.08% | 0.26% |
| Financial Health | ||
| Profit Margin (TTM) | 0.13% | 0.18% |
| Operating Margin (TTM) | 0.20% | 0.27% |
| Return on Equity (TTM) | 0.14% | 0.25% |
| Debt to Equity (MRQ) | 53.89 | 33.40 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹370.26 | ₹249.47 |
| Cash per Share (MRQ) | ₹84.74 | ₹23.47 |
| Operating Cash Flow (TTM) | ₹26.50B | ₹27.02B |
| Levered Free Cash Flow (TTM) | ₹19.91B | ₹19.11B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.04% | 0.83% |
| Last 12-Month Dividend | ₹1.00 | ₹35.00 |
Valuation & Enterprise Metrics Analysis: Mankind Pharma Ltd. vs Torrent Pharmaceuticals Ltd.
| Metric | MANKIND (Apr 24, 2026) | TORNTPHARM (Apr 26, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 53.43 | 61.35 |
| Forward P/E | 38.66 | 63.92 |
| PEG Ratio | -1.36 | 2.35 |
| Price to Sales (TTM) | 6.84 | 10.94 |
| Price to Book (MRQ) | 6.23 | 16.50 |
| Market Capitalization | ||
| Market Capitalization | ₹946.57B | ₹1.39T |
| Enterprise Value | ₹973.91B | ₹1.41T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.00 | 11.09 |
| Enterprise to EBITDA | 30.12 | 34.44 |
| Risk & Other Metrics | ||
| Beta | 0.39 | 0.19 |
| Book Value per Share (MRQ) | ₹370.26 | ₹249.47 |
Financial Statements Comparison: Mankind Pharma Ltd. vs Torrent Pharmaceuticals Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | MANKIND (2025) | TORNTPHARM (2025) |
|---|---|---|
| Revenue/Sales | 122.07B | 113.17B |
| Cost of Goods Sold | 35.69B | 28.84B |
| COGS % of Revenue | 29.2% | 25.5% |
| Gross Profit | 86.38B | 84.33B |
| Gross Margin | 70.8% | 74.5% |
| Research & Development | N/A | 304.20M |
| Operating Income (EBIT) | 25.16B | 29.26B |
| Operating Margin | 20.6% | 25.9% |
| EBITDA | 32.48B | 37.25B |
| EBITDA Margin | 26.6% | 32.9% |
| Pre-Tax Income | 25.16B | 26.73B |
| Pre-Tax Income % of Revenue | 20.6% | 23.6% |
| Income Tax | 5.10B | 7.62B |
| Income Tax % of Revenue | 4.2% | 6.7% |
| Net Income (Profit) | 20.11B | 19.11B |
| Profit Margin | 16.5% | 16.9% |
Balance Sheet & Liquidity Metrics
| Metric | MANKIND (2025) | TORNTPHARM (2025) |
|---|---|---|
| Cash & Equivalents | 4.07B | 5.73B |
| Total Current Assets | 69.88B | 56.23B |
| Total Current Assets % of Revenue | 57.2% | 49.7% |
| Total Current Liabilities | 56.64B | 47.17B |
| Total Current Liabilities % of Revenue | 46.4% | 41.7% |
| Long-Term Debt | 55.40B | 13.38B |
| Long-Term Debt % of Revenue | 45.4% | 11.8% |
| Total Shareholders Equity | 145.68B | 75.91B |
| Retained Earnings | 119.07B | N/A |
| Retained Earnings % of Revenue | 97.5% | 0.0% |
| Property, Plant & Equipment | 29.08B | 2.99B |
Cash Flow Statement Comparison
| Metric | MANKIND (2025) | TORNTPHARM (2025) |
|---|---|---|
| Operating Cash Flow | 26.50B | 27.02B |
| Operating Cash Flow % of Revenue | 21.7% | 23.9% |
| Capital Expenditures | -4.59B | -5.94B |
| Free Cash Flow | 18.83B | 19.73B |
| FCF Margin | 15.4% | 17.4% |
| Debt Repayment | -50.73B | -9.26B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | MANKIND | TORNTPHARM |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 412.83M | 338.45M |
| Float Shares | 112.84M | 103.94M |
| % Held by Insiders | 75.27% | 71.13% |
| % Held by Institutions | 17.86% | 14.81% |
| % Held by Public | 6.87% | 14.06% |
Dividend Analysis & Yield Comparison: Mankind Pharma Ltd. vs Torrent Pharmaceuticals Ltd.
| Metric | MANKIND | TORNTPHARM |
|---|---|---|
| Last 12-Month Dividend | ₹1.00 | ₹35.00 |
| Last 12-Month Dividend Yield | 0.04% | 0.83% |
| 3-Year Avg Annual Dividend | ₹0.33 | ₹32.33 |
| 3-Year Avg Dividend Yield | 0.04% | 0.52% |
| 3-Year Total Dividends | ₹1.00 | ₹97.00 |
| Ex-Dividend Date | Aug 08, 2025 | Feb 18, 2026 |